Drugs / 18F-T807
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04926259 | Nov 2021 → Dec 2024 | neurodegenerative disease | First Affiliated Hospital of Fujian Medical University | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02370524 | Jan 2015 → Jan 2016 | Alzheimer disease | Molecular NeuroImaging | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04604587 | Oct 2020 → Jul 2023 | cerebral amyloid angiopathy, intracerebral hemorrhage | National Taiwan University Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-T807 | “Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807” NCT04604587 ↗ |
| Modality | Diagnostic / imaging agent | “an investigational PET radioligand for imaging Tau” NCT02370524 ↗ |
| Route | Intravenous | “Each subject receive a single intravenous injection of 18F-T807” NCT04926259 ↗ |